Guardant Health, a startup company formed in 2012 by two former Illumina employees, recently announced its first product — a targeted next-gen sequencing-based assay that assesses circulating tumor DNA.

The test, Guardant 360, analyzes 54 oncogenes and tumor suppressor genes. It requires a patient blood sample and uses a proprietary target capture to zero in on the specified genes. Sequencing is done on Illuumina's HiSeq 2500 and turnaround time is two weeks. The company has not yet disclosed a price for its test, which is currently available via early access.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.